Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS Overrules FDA On Plan B OTC, Sends Teva Back To Drawing Board

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS Secretary Sebelius’ override appears to set a precedent of HHS intervention in an FDA product review.

You may also be interested in...



Panel Of Former US FDA Commissioners Make Renewed Call For Independent Agency

Former FDA heads reflected on instances when they experienced pressure from their higher-ups; speakers also offered praise for the job Commissioner Scott Gottlieb is doing at the agency. 

Gottlieb's Confirmation: He's Willing To Disagree With Trump, Sec. Price

Democrats test US FDA commissioner nominee's willingness to defend agency independence during confirmation hearing and probe potential conflicts of interest.

Gottlieb's Confirmation: Will Industry Ties Remain A Problem After The Hearing?

The US FDA commissioner does not generally get involved with day-to-day activities, former FDA chiefs say, but perception of bias could be a lasting problem.

Related Content

Related Companies

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel